type 2 diabetes

To understand Knowledge, Attitude and Practice (KAP) of physicians in the management of postprandial hyperglycaemia in type 2 diabetes. A questionnaire based cross sectional study was carried out with 105 physicians across India. The questionnaire was aimed to understand the management of postprandial hyperglycaemia, glycemic variation and comprehend the role of alpha glucosidase inhibitors from the Indian perspective. About 98% of physicians have reported that postprandial hyperglycaemia is an important factor contributing to glycemic variability. About 72% of physicians consider that voglibose, alone or in combination to other oral hypoglycaemic agents helps in reducing glycemic variability. Almost 88% of physicians consider that mouth dissolving formulation of voglibose will increase the compliance in their patients. Only 55% of physician’s have advised their patients to take voglibose during the first bite of meal. Physicians consider postprandial hyperglycaemia as an important contributing factor for glycemic excursions and consider voglibose either alone or in combination with other oral hypoglycaemic drugs would control glycemic variability. Similarly, the mouth dissolving voglibose would be a better option to increase patient compliance with respect to conventional voglibose.